Developability assessment

The therapeutic antibodies and their by-products (antibody fragments, conjugated, etc.) establish one of the most dynamic biopharmaceutical market segments today. Due to their intrinsic properties of specificity towards their target, towards their flexible affinity and due to their stability, antibo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	M.S. Médecine sciences 2019-12, Vol.35 (12), p.1163
Hauptverfasser:	Dumas, Jacques, Huille, Sylvain, Prades, Catherine
Format:	Artikel
Sprache:	fre
Schlagworte:	Antibodies, Monoclonal - biosynthesis Antibodies, Monoclonal - therapeutic use Biosimilar Pharmaceuticals - chemical synthesis Biosimilar Pharmaceuticals - chemistry Biosimilar Pharmaceuticals - therapeutic use Drug Development - economics Drug Development - methods Drug Development - standards Drug Industry - economics Drug Industry - methods Drug Industry - standards Humans Immunoconjugates - chemistry Immunoconjugates - metabolism Immunoconjugates - therapeutic use Immunoglobulin Fragments - biosynthesis Immunoglobulin Fragments - chemistry Immunoglobulin Fragments - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The therapeutic antibodies and their by-products (antibody fragments, conjugated, etc.) establish one of the most dynamic biopharmaceutical market segments today. Due to their intrinsic properties of specificity towards their target, towards their flexible affinity and due to their stability, antibodies became therapeutic agents of the very first choice. One of the challenges of this sector is to create antibodies of very good quality, more and more quickly, while having less and less consequent development costs in fine.
ISSN:	1958-5381
DOI:	10.1051/medsci/2019231